Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report) today and set a price target of $18.00. The company’s shares closed last Monday at $2.32, close to its 52-week low of $2.20.
According to TipRanks.com, Goldstein is a 1-star analyst with an average return of -0.8% and a 33.4% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Neoleukin Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Autolus Therapeutics with a $14.00 average price target.
Autolus Therapeutics’ market cap is currently $232.7M and has a P/E ratio of -1.42.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm’s portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
Read More on AUTL: